KRAS and cancer: Likewise, from the genetic perspective, while both models contained clonal hotspot mutations in RAS genes (Kras p.G12C in GL261-luc2 and Nras p.Q61L in CT2A-luc), which are important oncogenic drivers across multiple human cancers, such mutations have only been identified in <1% of huGBM tumors in TCGA.